Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.54 |
| ▸ | FOXO1 | Q12778 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | COMT | P21964 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22489158 | 0.89 | FGFR1 (0.50) | FGFR1FGFR2FGFR3FOXO1MAPT | |
| SCHEMBL24513588 | 0.88 | MAPT (0.63) | FOXO1MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL22489164 | 0.85 | COMT (0.64) | FGFR1FGFR2FGFR3FOXO1MAPT | |
| SCHEMBL22489165 | 0.83 | FOXO1 (0.72) | FGFR1FGFR2FGFR3FOXO1MAPT | |
| SCHEMBL22489161 | 0.83 | RAB9A (0.66) | FGFR1FGFR2FGFR3FOXO1MAPT | |
| SCHEMBL22489162 | 0.82 | FOXO1 (0.52) | FGFR1FGFR2FGFR3FOXO1MAPT | |
| SCHEMBL22488985 | 0.81 | MAPT (0.62) | FOXO1MAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL22489157 | 0.81 | FOXO1 (0.68) | FGFR1FGFR2FGFR3FOXO1MAPT | |
| SCHEMBL12252473 | 0.80 | MAPT (0.52) | FGFR1FGFR2FGFR3FOXO1MAPT | |
| SCHEMBL24513591 | 0.79 | NPC1 (0.60) | FOXO1MAPTKDM4EKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-06-16 | — | — | US | disclosed |
| WO-2020198351-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | FOXO1, FOXO3, FOXK1 | FGFR1 311/4885FGFR2 1119/4885FGFR3 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.